<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00546520</url>
  </required_header>
  <id_info>
    <org_study_id>BY9010/M1-125</org_study_id>
    <nct_id>NCT00546520</nct_id>
  </id_info>
  <brief_title>Effect of Inhaled Ciclesonide in Adult Patients With Asthma (BY9010/M1-125)</brief_title>
  <official_title>A 3-period Double-blind, Cross-over Study on the Onset of Action of Inhaled Ciclesonide (7 Days of 400 mcg Sid Versus 800 mcg Bid Versus Placebo) on Airway Responsiveness to Adenosine Monophosphate (AMP), Sputum Eosinophiles and Exhaled Breath Nitric Oxide (NO) in Patients With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ciclesonide is a novel inhaled corticosteroid for the treatment of asthma. In this study the
      effect of ciclesonide on airway hyperresponsiveness (AHR), exhaled nitric oxide (NO), and
      induced sputum inflammatory biomarkers will be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <completion_date type="Actual">June 2002</completion_date>
  <primary_completion_date type="Actual">June 2002</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PC20FEV1 (AMP)</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Baseline FEV1 from spirometry, exhaled NO, eosinophils, basophils, and mast cells determined from induced sputum; Safety variables: Physical examination, vital signs, ECG, laboratory work-up, and adverse events</measure>
  </secondary_outcome>
  <enrollment type="Actual">21</enrollment>
  <condition>Asthma</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclesonide</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main inclusion criteria:

          -  Out-patients

          -  Written informed consent

          -  History of atopic disease

          -  History of perennial bronchial asthma for at least 6 months as defined by ATS criteria

          -  Current use of only inhaled short acting beta-2-agonist as required (for at least 4
             weeks prior to baseline period B0)

          -  Stable asthma, i.e. no exacerbation or relevant respiratory tract infection within 2
             months prior to study start

          -  FEV1 â‰¥ 70% predicted

          -  Hyperreactivity to AMP (PC20FEV1 &lt; 25 mg/ml)

          -  Good health with the exception of asthma

          -  Non-smokers as well as ex-smokers with either = 10 pack-years or more than 6 months of
             smoking abstinence

        Main exclusion criteria:

          -  Concomitant severe diseases or diseases which are contraindications for the use of
             inhaled steroids (e.g. lung tuberculosis)

          -  Clinically relevant abnormal laboratory values suggesting an unknown disease and
             requiring further clinical evaluation

          -  Use of systemic steroids 4 weeks (injectable depot steroids 6 weeks) before entry into
             the baseline period, or more than 3 times during the last 6 months

          -  Pregnancy or intention to become pregnant during the course of the study, breast
             feeding, lack of safe contraception in heterosexually active female patients of
             child-bearing potential, or postmenopausal for less than one year

          -  COPD (i.e. chronic bronchitis or emphysema) and/or other relevant lung diseases

          -  Known or suspected hypersensitivity to inhaled steroids or to the other excipients of
             the metered dose inhalers

          -  Immunotherapy within one month prior to B0 and/or during the entire study duration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>AstraZeneca AstraZeneca</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>&quot;Altana Pharma/Nycomed&quot;</name>
      <address>
        <city>London</city>
        <zip>SW3 6NP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2007</study_first_submitted>
  <study_first_submitted_qc>October 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2007</study_first_posted>
  <last_update_submitted>December 5, 2016</last_update_submitted>
  <last_update_submitted_qc>December 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Asthma</keyword>
  <keyword>Ciclesonide</keyword>
  <keyword>Airway hyperresponsiveness</keyword>
  <keyword>Sputum</keyword>
  <keyword>Nitric oxide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
    <mesh_term>Ciclesonide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

